CORCEPT THERAPEUTICS INC - Common Stock (CORT) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CORT on Nasdaq
Shares outstanding
105,863,294
Price per share
$34.80
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
77,185,883
Total reported value
$6,410,521,140
% of total 13F portfolios
0.01%
Share change
-1,874,604
Value change
-$137,349,399
Number of holders
421
Price from insider filings
$34.80
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of CORCEPT THERAPEUTICS INC - Common Stock (CORT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 11% -14% $846,969,867 -$132,857,230 11,539,099 -14% BlackRock, Inc. 30 Jun 2025
INGALLS & SNYDER LLC 7.8% $598,561,589 8,173,721 INGALLS & SNYDER LLC 31 Dec 2024
BELANOFF JOSEPH K 6.3% $499,599,592 6,822,335 Joseph K. Belanoff 31 Dec 2024

As of 30 Sep 2025, 421 institutional investors reported holding 77,185,883 shares of CORCEPT THERAPEUTICS INC - Common Stock (CORT). This represents 73% of the company’s total 105,863,294 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of CORCEPT THERAPEUTICS INC - Common Stock (CORT) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 12,047,830 -3.9% 0.02% $1,001,295,112
VANGUARD GROUP INC 9% 9,537,071 -1.5% 0.01% $792,625,970
INGALLS & SNYDER LLC 7.3% 7,697,984 -0.32% 21% $639,779,000
RENAISSANCE TECHNOLOGIES LLC 5.8% 6,089,347 -2.8% 0.67% $506,085,629
Parallel Advisors, LLC 3.7% 3,871,452 +0.01% 5.9% $321,756,376
STATE STREET CORP 2.8% 2,970,400 +0.09% 0.01% $246,869,944
FMR LLC 2.1% 2,201,938 +62% 0.01% $183,003,047
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,934,272 +0.97% 0.01% $161,530,218
DIMENSIONAL FUND ADVISORS LP 1.8% 1,892,448 -9.3% 0.03% $157,284,888
AQR CAPITAL MANAGEMENT LLC 1.4% 1,507,209 +547% 0.08% $125,264,121
MORGAN STANLEY 1.1% 1,186,977 -26% 0.01% $98,649,849
Clearbridge Investments, LLC 1.1% 1,161,828 -0.52% 0.07% $96,559,510
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1% 1,070,281 +31% 0.01% $88,951,054
TD Asset Management Inc 0.9% 956,136 +17% 0.06% $79,464,463
JPMORGAN CHASE & CO 0.8% 849,864 +223% 0% $70,632,217
Epoch Investment Partners, Inc. 0.8% 847,104 +11% 0.39% $70,402,813
Cerity Partners LLC 0.72% 758,426 +1.6% 0.1% $63,032,785
Invesco Ltd. 0.69% 732,583 -29% 0.01% $60,884,974
FIRST TRUST ADVISORS LP 0.68% 720,224 +34% 0.04% $59,857,775
NORTHERN TRUST CORP 0.61% 642,326 -1.5% 0.01% $53,383,715
Bank of New York Mellon Corp 0.57% 601,499 -5.8% 0.01% $49,990,559
D. E. Shaw & Co., Inc. 0.55% 584,098 -13% 0.04% $48,544,385
Boston Trust Walden Corp 0.53% 562,261 -1.7% 0.34% $46,729,511
UBS Group AG 0.52% 549,938 +414% 0.01% $45,705,347
Driehaus Capital Management LLC 0.5% 526,602 +9.4% 0.31% $43,765,892

Institutional Holders of CORCEPT THERAPEUTICS INC - Common Stock (CORT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,055,319 $38,473,021 -$32,543,555 $34.80 30
2025 Q3 77,185,883 $6,410,521,140 -$137,349,399 $83.11 421
2025 Q2 78,953,366 $5,792,808,674 -$256,092,991 $73.40 418
2025 Q1 81,954,269 $9,118,688,561 -$126,808,558 $114.22 408
2024 Q4 84,197,994 $4,242,065,667 -$207,314,469 $50.39 362
2024 Q3 88,403,089 $4,090,692,212 +$3,394,284 $46.28 316
2024 Q2 89,225,655 $2,899,048,485 -$128,567,810 $32.49 282
2024 Q1 93,600,393 $2,357,405,516 +$206,853,940 $25.19 283
2023 Q4 84,732,406 $2,752,093,285 +$61,774,959 $32.48 269
2023 Q3 83,019,792 $2,261,938,980 +$53,168,814 $27.24 244
2023 Q2 81,489,147 $1,813,024,077 -$128,901,748 $22.25 224
2023 Q1 87,299,563 $1,890,881,420 +$97,037,592 $21.66 231
2022 Q4 83,493,481 $1,696,055,001 -$86,283,839 $20.31 241
2022 Q3 87,114,680 $2,234,275,240 +$46,310,026 $25.64 225
2022 Q2 85,057,351 $2,023,773,420 +$98,901,040 $23.78 214
2022 Q1 81,373,846 $1,836,938,219 +$19,570,522 $22.52 214
2021 Q4 80,562,329 $1,594,701,243 -$8,205,377 $19.80 199
2021 Q3 80,869,592 $1,591,453,895 +$4,936,347 $19.68 193
2021 Q2 80,507,190 $1,769,402,198 -$27,080,717 $22.00 193
2021 Q1 81,631,723 $1,941,273,564 -$37,899,526 $23.79 205
2020 Q4 83,389,910 $2,180,799,586 -$129,685,932 $26.16 219
2020 Q3 89,228,523 $1,552,636,140 +$5,152,396 $17.40 215
2020 Q2 89,585,381 $1,506,658,948 +$28,288,519 $16.82 215
2020 Q1 88,309,062 $1,050,027,497 -$9,509,056 $11.89 198
2019 Q4 89,063,766 $1,077,729,997 +$45,482,106 $12.10 199
2019 Q3 85,131,011 $1,203,527,878 -$5,445,594 $14.13 190
2019 Q2 86,279,264 $961,989,210 -$5,849,517 $11.15 178
2019 Q1 87,458,593 $1,027,102,142 -$43,866,557 $11.74 202
2018 Q4 90,986,215 $1,215,139,760 +$16,037,355 $13.36 218
2018 Q3 89,613,248 $1,256,182,217 +$22,194,353 $14.02 201
2018 Q2 87,598,857 $1,376,792,174 -$4,897,891 $15.72 212
2018 Q1 87,899,835 $1,446,070,158 -$15,306,978 $16.45 210
2017 Q4 88,793,405 $1,603,715,912 +$258,953,650 $18.06 184
2017 Q3 74,126,241 $1,430,343,350 +$88,254,904 $19.30 188
2017 Q2 69,833,354 $824,271,874 +$108,930,274 $11.80 155
2017 Q1 60,673,852 $664,929,310 +$151,136,418 $10.96 133
2016 Q4 53,330,829 $387,201,104 +$44,065,843 $7.26 135
2016 Q3 47,182,349 $306,733,706 +$9,894,257 $6.50 110
2016 Q2 45,723,356 $249,638,429 +$64,877,791 $5.46 109
2016 Q1 33,883,343 $158,556,671 -$1,367,110 $4.68 95
2015 Q4 34,152,793 $170,039,914 -$231,311 $4.98 95
2015 Q3 34,255,309 $128,827,965 +$5,433,569 $3.76 94
2015 Q2 32,478,045 $195,173,928 +$11,582,180 $6.01 78
2015 Q1 30,334,599 $169,851,880 +$9,777,388 $5.60 60
2014 Q4 28,775,574 $86,298,641 -$1,434,944 $3.00 50
2014 Q3 29,312,101 $78,551,805 -$1,074,865 $2.68 53
2014 Q2 29,700,124 $83,152,770 -$5,827,268 $2.80 61
2014 Q1 30,460,908 $132,741,801 +$10,483,820 $4.36 58